Advances in Obstetrics and Gynaecology



Research Article

Adv in Obs and Gynec: AOAG-101

Signatures Containing miR-133a identified from Large Scale Micro RNA Expression Profiling in Bladder Cancer Tissue

Shuai Jiang¹, Miaojun Zhu², Fengwu Zhang², Jun Hou³, Hang Wang¹, Li Liu¹, Hailong Wang⁴, Tom Tang⁴, Ruoying Tan^{2**}, Zengxia Li^{5***}, Jianming Guo^{1*}

¹Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China
²Biovue Technology (China) Ltd., Shanghai, China
³Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China
⁴First Dimension Bio-Sciences (China), Co., Ltd, Su Zhou, China
⁵Key Laboratory of Molecular Medicine, Ministry of Education and Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai, China

*Corresponding author:

^{*}Jianming Guo, Department of Urology Surgery, Zhongshan Hospital Fudan University; 180 Fenlin Road, 200032, Shanghai, China. Tel: +8621640419902303; Email: guo.jianming@zs-hospital.sh.cn

**Ruoying Tan, Biovue Technology (China) Ltd.; 400, building no.6, 333 Guipin Road, 200031, Shanghai, China. Email: roy.tan@biovuetech.com

***Zengxia Li, Email: Key Laboratory of Molecular Medicine, Ministry of Education and Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai, China. Email: lizengxia@fudan.edu.cn

Citation: Jiang S, Zhu M, Zhang F, Hou J, Wang H, Liu L, Wang H, Tang T, Tan R, Li Z, Guo J (2018) Signatures containing miR-133a identified from Large Scale Micro RNA Expression Profiling in Bladder Cancer Tissue. Adv in Obs and Gynec: AOAG-101.

Received Date: 27 July, 2018; Accepted Date: 02 August, 2018; Published Date: 13 August, 2018

Abstract:

1.1. Objective: According large scale miRNA expression profiling of bladder cancer (BC) tissue samples and adjacent normal tissue samples from patients with bladder cancer, we discovered several miRNA expression signatures containing miR-133a correlated with BC diagnosis, that has shed light inprospective molecular mechanism of miRNA-133a and other miRNAs in the tumorigenesis of BC.Two miRNA clusters of miR183-96-and miR200 are significantly up-regulated in bladder cancer tissue samples compared with those in normal tissue samples, suggesting theses miRNAs may be involved in bladder cancer development.

1 Vol. 2018, Issue 01

1.2. Methods: According expression data of large scale miRNA profiling in BC tissue sample pool and in adjacent normal bladder tissue sample pool, we selected differential expressed miRNAs between two pools, and generated one 384-well panel consists of primers to detect the selected miRNAs and controls. This panel was used to profile miRNA expression in each individual sample in training group and in double blind test group. Data analysis was performed using a machine learning approach of a Support Vector Machine classifier with a Student's t-test feature selection procedure.

1.3. Results: We identified signatures consisting of three or four miRNAs with optimum classification performance; all identified signatures containing hsa-miR-133a could distinguish BC cases from normal controls with an accuracy of 100% in training model and accuracy over 95% in double blinding test.

1.4. Conclusions: miRNA signatures containing hsa-miR-133a may be used as biomarkers in BC diagnosis and serves as a complement to cystoscopy.

1. Introduction

Bladder cancer (BC) is the second most common urological malignancy in humans globally with an estimated 430, 000 new cases diagnosed and 165,000 deaths in 2016 [1-3]. In China, BC is the most common genitourinary cancer [4]. The gold standards for the initial diagnosis of BC are combination of cystoscopy and biopsy. However, these methods are invasive, uncomfortable, and costly [5,6]. Urinary cytology is of high specificity (90%-95%), but the sensitivity is relative low (~30%). Furthermore, several new urine-based tests for BC, such as BC antigen stat, nuclear matrix protein 22 (NMP22, Sysmex Corp., Kobe, Japan), and FISH (UroVysion, Abbott Molecular Inc, Des Plaines, IL, USA), have been approved for clinical application. However, these new urinary markers have not been widely applied because they have relatively low specificities (60%–80%) compared with urinary cytology, despite of their higher sensitivities (50%-70%) [7]. Accordingly, the development of highly accurate BC diagnostic biomarkers is urgently needed.Since first miRNA was discovered in 1993, miRNAs have been shown to regulate gene expression at posttranscriptional level by binding through partial sequence homology to the 3' untranslated region or through complete sequence homology to the coding region of target mRNAs to cause repression of translation or mRNA degradation [8-10]. The accumulating data indicate that miRNAs play important roles in tumorigenesis, metastasis, and drug responsiveness in BC and in other urological cancers [11-14].

In this study, we have applied Biovue'sqRT-PCR miRNA assay platform to profile large scale miRNAs

(1900 miRNAs) in a set of BC tissue samples and in adjacent normal tissue samples and have identified signatures of three or four-miRNA that can distinguish BC patients from normal controls with high sensitivity and specificity. These identified signatures all contain hsa-miRNA-133a thus indicating the importance of hsa-miRNA-133a in tumorigenesis and diagnosis of BC.

2. Materials and Methods

2.1. Collection of bc Tissue Samples

The study comprised 30 patients at Department of Urology, Zhongshan Hospital (Fudan University, Shanghai, China) during the period May-November 2016. All the tissue samples in our study were divided into two groups, training group and doubleblind test group. Training group contains 19 BC tissues samples and 19 adjacent normal tissue samples as normal controls. Double blinding test group contains 11 BC tissue samples and 10 adjacent normal tissue samples. All tissue samples were immediately frozen in liquid nitrogen after they were being removed from body and stored at-80°C. The demographics and clinical features of the patients are listed in (**Table 1**).

| | | Diagnost | ic Model | Validation | | |
|-------------------------|-----|--------------------|------------------|--------------------|------------------|--|
| Demographic features | | Adjacent (n=19) | Cancer (n=19) | Adjacent (n=10) | Cancer (n=11) | |
| Average age (range) | | 73.0 (47-90) | 73.0 (47-90) | 61.4 (46-77) | 66.1 (46-88) | |
| Gender: male/females, n | | 16/3 | 16/3 | 8/1 | 10/1 | |
| | Tis | 1 | l | | | |
| | Ι | 15 | | 10 | | |
| Stage | II | 2 | | | | |
| | III | 1 | l | | | |
| | IV | | | 1 | | |

Table 1: Demographic and Clinical Characteristics of Participants.

Abbreviation: Tis : Tumor in situ.

2.2. miRNA Isolation and cDNA Synthesis

Total RNA was isolated from < 50 mg of frozen tissue sample with miRNeasy Mini Kit (Qiagen, 217004) according to the manufacturer's instructions. First strand cDNA was generated from total RNA sample in reverse transcription by using Sharp vueTMmiRNA First Strand Kit (Biovue, 9000004) following manufacturer's protocol. The reactions were incubated at 37 °C for 60 minutes, and then were inactivated by incubation at 95 °C for 10 minutes by using Gene Amp PCR 9700 Thermocycler (Applied Biosystems).

2.3. Quantitative Real-Time PCR Assay

Single tube miRNA assays were used to detect miRNAs by SharpvueTM2x Universal qPCR Master Mix High Rox (Biovue, 9000008) and SharpvueTM Human miRNA Primer Array (Biovue) according to manufacturer's protocol. The level of miRNA expression was quantified using ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). The reactions were incubated in a 384-well optical plate at 95°C for 10 minutes, following by 3 cycles of 96°C for 5 seconds and 60°C for 1 minute, then 37 cycles of 96°C for 5 seconds and 60°C for 30 seconds and run melting curve at last. SYBR was set as reporter and Rox was set as reference respectively.

2.4. BC miRNA Panel

Expressions of miRNAs in BC tissue samples pool and in adjacent normal tissue samples pool were detected by primers for 1900 miRNAs and controls in five 384-well plates. Each plate contains primers to detect 380 miRNAs, 2 endogenous controls, one spiking control and one no template control. We selected differential expressed miRNAs between BC tissue samples pool and adjacent normal tissue samples pool; and generated one 384-well panel to detect 380 selected miRNAs, two endogenous controls, one spiking control and one no template control. This panel will be used to profile miRNA expression of each individual sample in training group and in double blind test group.

3. Result

3.1. Clinical and Pathological Findings

The clinical features of samples collected from epithelial of patients (30 BC tissue samples; 29 adjacent normal tissue samples) in our study are summarized in Table 1. 30 bladder cancer tissue samples include 1 case of stage Tis (in training group), 25 cases of stage I (15 cases in training group and 10 cases in double blind group), 2 cases of stage II (including one of low-lever urothelial carcinoma in training group), 1 cases of stage III (in training group) and 1 cases of stage IV (in double blind group). 29 adjacent normal tissue samples include 19 cases in training group and 10 cases in double blind test group.

3.2. Biomarker Selection Based on qRT-PCR

The miRNA expression data from real-time PCR was performed by using R and package e1071 with some modifications as the following: First, set Ct value as 32 to any miRNAs if their measured Ct values were greater than 32. Then, we compared mean Ct-value of each miRNA between tumor tissue and control tissue for 365microRNAs (15 miRNAs without expression were removed from analysis), 2 endogenous controls. There are many miRNAs with significant higher Ct-value in cancer tissue were shown in (**Figure 1**). Afterwards, we did T-test for

each miRNA. 70 miRNAs with P-value < 0.001 were displayed in (**Figure 2**).



Fig. 1:Schematic of dysregulation miRNAs in BC (red).



Figure 2:Schematic of dysregulation miRNAs in BC (red). The volcanoplot of miRNAs with P-value.

In order to prove there are tumor related markers and to find out these markers, we trained a SVM model, and predicted 20 other samples. The model was built as the following: a). we produced 66430 new variables by computing the difference between Ct of each tow miRNAs and got 66796 total variables with the original 366 variables. b). we did T-test on all these variables and took 2 variables with the greatest P-value and some variables with smallest P-value. Until we had got 20 candidate miRNAs those variables included. c). for each miRNA subset with markers less than or equal to 12 of the 20 candidate miRNAs, we trained a SVM model with default parameters by function SVM and evaluated the accuracy by 50 times 10-fold cross validation. d) Then 10 subsets with the best accuracy and AUC were selected and 10 SVMs based on these 10 marker subsets were trained by total 38 samples and the stat of 21 blind samples was predicted. They all showed good performances on blind samples with accuracy greater than 0.95. The best one was selected for further analysis.

3.3. miRNA Expression Profiling in BC And Normal Controls

To identify BC specific miRNA expression signatures as biomarkers to diagnose BC, we applied the panel to profile miRNA expression of 38 tissue samples in training group, including 19 BC tissue samples and 19 matched adjacent normal tissue samples. The 365 dysregulated microRNAs and two endogenous controls in BC tissue samples and in adjacent normal tissue samples were presented in the (Supplemental Table 1). There were 121 microRNAs, including miR-182, miR-431, miR-183, miR-429 and miR-425 etc., with a higher expression levels in the BC tissues compared with adjacent normal tissues. In contrast, 245 microRNAs, such as miR-1, miR-133a, miR-133b miR-125b miR-143 and miR-145 etc, had a lower expression level in the BC tissues relative to adjacent normal tissues. The aberrant expression levels of miRNAs were summarized in (Table 2).

| miRNA name | mean Normal | Log ₂ FC | T-value | P-value |
|-----------------|-------------|---------------------|----------------|----------|
| hsa-miR-1 | 26.12782155 | 4.8691869 | 9.809440884 | 5.82E-12 |
| hsa-miR-30a | 22.60102595 | 3.08240765 | 9.287222774 | 5.48E-11 |
| hsa-miR-133a | 24.4354524 | 3.10808475 | 8.931966341 | 1.19E-10 |
| hsa-miR-4328 | 21.0968902 | 3.91722335 | 8.532184649 | 8.06E-10 |
| hsa-miR-143# | 25.0985113 | 3.42840055 | 8.006753062 | 1.29E-09 |
| hsa-miR-143 | 19.7855096 | 4.1667027 | 7.83836364 | 2.59E-09 |
| hsa-miR-145 | 18.30939145 | 4.5212111 | 8.084599629 | 4.80E-09 |
| hsa-miR-376c | 25.36776165 | 3.4553682 | 7.558748119 | 9.56E-09 |
| hsa-miR-125b | 20.29446115 | 4.6285196 | 7.775000198 | 1.13E-08 |
| hsa-miR-100 | 23.00215805 | 4.40793215 | 7.77647622 | 1.58E-08 |
| hsa-miR-199b-3p | 20.7305781 | 4.1213263 | 7.973725661 | 1.61E-08 |
| hsa-miR-99a | 23.36811305 | 4.5790223 | 7.746394335 | 3.30E-08 |
| hsa-miR-199a-5p | 22.08252775 | 3.9837205 | 7.058102887 | 4.01E-08 |
| hsa-miR-497 | 24.0621254 | 2.91987705 | 7.134383565 | 4.94E-08 |
| hsa-miR-376a | 26.4500204 | 3.4226842 | 7.246161876 | 5.76E-08 |
| hsa-miR-195 | 23.15245275 | 3.00588535 | 6.595963782 | 1.09E-07 |
| hsa-miR-154 | 26.59476795 | 3.0009218 | 6.989134323 | 1.72E-07 |
| hsa-miR-139-5p | 26.58507925 | 2.0498703 | 6.217934445 | 3.22E-07 |
| hsa-miR-127-3p | 25.1306052 | 2.2363153 | 6.219988897 | 3.39E-07 |
| hsa-miR-379 | 29.15859985 | 2.23430305 | 6.093823941 | 4.29E-07 |
| hsa-miR-152 | 25.1137449 | 2.8155216 | 6.427856879 | 4.53E-07 |
| hsa-miR-495 | 27.95195155 | 2.5630645 | 6.082969797 | 1.32E-06 |
| hsa-miR-133b | 27.0639709 | 2.0207833 | 5.912748166 | 1.33E-06 |
| hsa-miR-377 | 25.89236105 | 3.2962058 | 6.39185024 | 1.48E-06 |
| hsa-miR-136 | 25.0941168 | 3.2224151 | 5.970151312 | 1.51E-06 |
| hsa-miR-136# | 26.87362035 | 3.20967815 | 5.7729383 | 1.57E-06 |
| hsa-miR-140-3p | 25.4251528 | 2.45418445 | 5.679138579 | 1.60E-06 |
| hsa-miR-150 | 24.11973495 | 3.6107569 | 5.717103638 | 1.87E-06 |
| hsa-miR-574-3p | 23.36441105 | 1.79655005 | 5.469180968 | 3.79E-06 |
| hsa-miR-337-3p | 26.6682857 | 2.07009815 | 5.594781395 | 4.07E-06 |
| hsa-miR-130a | 23.46221215 | 2.4440971 | 5.745567912 | 4.11E-06 |
| hsa-miR-29a | 20.6555566 | 2.386061 | 5.668752022 | 4.33E-06 |
| hsa-miR-101 | 21.5610767 | 1.8347093 | 5.299070261 | 5.43E-06 |
| hsa-miR-342-3p | 23.18032995 | 1.9355929 | 5.237219218 | 1.45E-05 |
| hsa-miR-126# | 22.86494995 | 1.9387173 | 4.937661612 | 1.96E-05 |
| hsa-miR-222 | 23.4050734 | 1.85868785 | 4.942452211 | 2.20E-05 |
| hsa-miR-365b-3p | 24.1221182 | 1.22701895 | 4.847253766 | 3.32E-05 |
| hsa-let-7c | 24.06564905 | 2.2533086 | 4.646655955 | 3.98E-05 |
| hsa-miR-28-3p | 25.65795785 | 1.2129748 | 4.651457821 | 4.09E-05 |
| hsa-miR-27b | 22.46738325 | 1.6925897 | 4.621989619 | 4.53E-05 |
| hsa-miR-431 | 27.33753895 | -1.7050862 | -4.620089861 | 4.77E-05 |
| hsa-miR-451 | 21.8264741 | 2.1363373 | 4.468465735 | 6.98E-05 |

5 Vol. 2018, Issue 01

| hsa-miR-551b | 25.33340815 | 3.03985395 | 4.508074422 | 7.56E-05 | |
|-----------------|-------------|-------------|--------------|-------------|--|
| hsa-miR-320c | 23.24441335 | 1.41644265 | 4.478917155 | 8.59E-05 | |
| hsa-miR-543 | 29.7072064 | 1.3195017 | 4.36105705 | 0.000101719 | |
| hsa-miR-182 | 28.69664615 | -1.9300384 | -4.272721358 | 0.000151213 | |
| hsa-miR-193b | 23.1125698 | 1.0128699 | 4.18768074 | 0.000168706 | |
| hsa-miR-342-5p | 29.4783259 | 1.38146835 | 4.183250867 | 0.000177017 | |
| hsa-miR-1247 | 22.3717192 | 1.23820375 | 4.138444581 | 0.000193647 | |
| hsa-miR-328 | 25.83411935 | 1.024637 | 4.067152197 | 0.000235068 | |
| hsa-miR-126 | 21.15470095 | 1.7589386 | 4.016215178 | 0.000283073 | |
| hsa-miR-10b | 24.7410833 | 1.4424195 | 4.065717946 | 0.000290896 | |
| hsa-miR-338-3p | 25.78045215 | 2.148419 | 3.955388217 | 0.000322289 | |
| hsa-miR-140-5p | 28.2960132 | 1.8576039 | 3.943014528 | 0.000337715 | |
| hsa-miR-369-3p | 28.4255048 | 1.6673728 | 4.001696311 | 0.000376451 | |
| hsa-miR-183 | 28.4274269 | -1.72647045 | -3.866474124 | 0.0004299 | |
| hsa-miR-429 | 25.01997015 | -1.48664115 | -3.844260434 | 0.000447105 | |
| hsa-miR-142-5p | 24.57882015 | 2.3212409 | 3.844958064 | 0.000481869 | |
| hsa-miR-30e# | 25.2996504 | 1.54164295 | 3.780538 | 0.000554659 | |
| hsa-miR-425 | 27.31893245 | -0.98565215 | -3.711287716 | 0.00066976 | |
| hsa-miR-24 | 21.9793475 | 1.45237895 | 3.696846761 | 0.000700445 | |
| hsa-miR-532-5p | 27.0696411 | 0.96784885 | 3.645865378 | 0.000797014 | |
| hsa-miR-132 | 26.4796401 | 1.51286615 | 3.655198409 | 0.000893664 | |
| hsa-miR-191# | 30.9403011 | -0.66744925 | -3.598585801 | 0.000910332 | |
| hsa-miR-23b | 21.7122885 | 1.83916365 | 3.598870952 | 0.000931943 | |
| hsa-miR-221 | 25.57643955 | 1.47041835 | 3.619747281 | 0.00094584 | |
| hsa-miR-409-3p | 28.0150883 | 1.45061025 | 3.643228525 | 0.000970027 | |
| hsa-miR-186 | 24.5825067 | 0.9065164 | 3.568946078 | 0.001015458 | |
| hsa-miR-383 | 26.53589485 | 0.8543973 | 3.541428863 | 0.001103413 | |
| hsa-miR-4457 | 25.88232885 | 1.52570425 | 3.548862709 | 0.001120198 | |
| hsa-let-7i# | 25.55904145 | 1.32723705 | 3.526383583 | 0.001199008 | |
| hsa-miR-4787-3p | 24.5164283 | -0.8828859 | -3.414370137 | 0.00153735 | |
| hsa-miR-142-3p | 22.3634303 | 2.57962 | 3.410067456 | 0.001554499 | |
| hsa-miR-4515 | 23.11883335 | -1.3588254 | -3.426627311 | 0.00160518 | |
| hsa-miR-365 | 24.77483395 | 1.019026 | 3.453564069 | 0.001667241 | |
| hsa-miR-323-3p | 30.3736771 | 1.06185165 | 3.416645217 | 0.001729454 | |
| hsa-miR-141# | 30.42505505 | -1.36608445 | -3.333558522 | 0.001993619 | |
| hsa-miR-3610 | 22.76108095 | -1.15089165 | -3.340350091 | 0.002009853 | |
| hsa-miR-210 | 26.5849375 | -1.2365398 | -3.316575134 | 0.002099143 | |
| hsa-miR-340 | 27.5344029 | 1.40211665 | 3.359967783 | 0.002116023 | |
| hsa-miR-148a | 22.63442665 | 1.222918 | 3.314373401 | 0.002204698 | |
| hsa-miR-320b | 23.2907638 | 0.75952705 | 3.280475204 | 0.002228309 | |
| hsa-miR-23a | 21.59763405 | 1.3045986 | 3.28322114 | 0.0023896 | |
| hsa-miR-155 | 27.46101985 | 1.8160122 | 3.235218869 | 0.002520089 | |
| hsa-miR-196b | 25.9830149 | 1.7902629 | 3.195800366 | 0.002824899 | |
| hsa-miR-656 | 28.94392765 | 0.89953625 | 3.063244039 | 0.004027979 | |

6 Vol. 2018, Issue 01

| hsa-miR-660 | 27.185685 | 0.7636651 | 3.066741473 | 0.004091327 | |
|-----------------|-------------|-------------|--------------|-------------|--|
| hsa-let-7i | 22.68492035 | 1.3000338 | 3.05140275 | 0.004167271 | |
| hsa-miR-3529 | 30.1631947 | 0.70401995 | 3.001770901 | 0.004748783 | |
| hsa-let-7b# | 27.279987 | 0.732047 | 2.993056875 | 0.004871397 | |
| hsa-miR-144# | 30.8821511 | 0.8829912 | 3.067629297 | 0.004952988 | |
| hsa-miR-548q | 31.32132105 | 0.45014005 | 2.957800399 | 0.006153716 | |
| hsa-miR-493 | 30.0825144 | 0.6951375 | 2.897813094 | 0.006210302 | |
| hsa-miR-223 | 23.44406645 | 1.97853525 | 2.919699876 | 0.006528151 | |
| hsa-miR-3614-3p | 29.59248965 | -0.984494 | -2.86694845 | 0.006724513 | |
| hsa-miR-532-3p | 26.78098585 | 0.65564045 | 2.862324396 | 0.006863026 | |
| hsa-miR-5001-5p | 25.71753005 | 1.05425915 | 2.866148314 | 0.006888698 | |
| hsa-miR-505 | 27.19126775 | 0.67007905 | 2.855420334 | 0.00694156 | |
| hsa-miR-362-3p | 27.6832793 | 0.82100295 | 2.840258198 | 0.007204649 | |
| hsa-miR-3135b | 24.97284205 | 0.6417884 | 2.777500699 | 0.008481823 | |
| hsa-miR-592 | 31.13443675 | 0.66345465 | 2.738041497 | 0.0095927 | |
| hsa-miR-212 | 29.5486406 | 1.0008928 | 2.729779462 | 0.009597216 | |
| hsa-miR-196a | 27.38908385 | 1.10877205 | 2.72659871 | 0.009653931 | |
| hsa-miR-26a | 21.32681625 | 1.69057045 | 2.713278386 | 0.009958922 | |
| hsa-miR-361-3p | 28.12515965 | 0.9541058 | 2.711820581 | 0.009994861 | |
| hsa-miR-432 | 28.36620585 | 0.81835125 | 2.714243032 | 0.0101904 | |
| hsa-miR-1273 | 31.47666495 | -0.525494 | -2.679633285 | 0.011156313 | |
| hsa-miR-1470 | 24.80158215 | -0.87661205 | -2.667075277 | 0.011180228 | |
| hsa-miR-449b | 26.96619415 | -0.66588595 | -2.647380932 | 0.012146338 | |
| hsa-miR-4646-3p | 22.8328203 | 0.82195005 | 2.687707151 | 0.012173562 | |
| hsa-miR-1179 | 22.78256425 | -0.3981945 | -2.615021723 | 0.012733052 | |
| hsa-let-7b | 21.12472435 | 1.1289838 | 2.610223587 | 0.012894397 | |
| hsa-miR-1260 | 23.5983059 | -0.87562655 | -2.59199796 | 0.013496655 | |
| hsa-miR-3193 | 26.76498135 | 0.83129875 | 2.606812743 | 0.013614125 | |
| hsa-miR-27a | 20.92300265 | 0.9000644 | 2.575819125 | 0.014270306 | |
| hsa-miR-26b | 22.07461815 | 1.29933495 | 2.539189591 | 0.015339391 | |
| hsa-miR-30d | 25.2785083 | 0.564175 | 2.520050052 | 0.016276762 | |
| hsa-miR-3907 | 22.6478882 | 0.91337795 | 2.511927544 | 0.016814744 | |
| hsa-miR-30e | 23.58118445 | 0.6111057 | 2.490614312 | 0.017472739 | |
| hsa-miR-424 | 24.251826 | 1.15479345 | 2.491208423 | 0.018049261 | |
| hsa-miR-770-5p | 26.96190865 | -1.3695525 | -2.446231884 | 0.019913924 | |
| hsa-miR-146b-5p | 25.450884 | 1.33221555 | 2.453154447 | 0.01994029 | |
| hsa-miR-1181 | 22.0476171 | -0.766908 | -2.428060122 | 0.020262004 | |
| hsa-miR-3162-3p | 24.53635555 | -0.55586185 | -2.426201684 | 0.020573687 | |
| hsa-miR-29c | 19.6668291 | 1.0106059 | 2.424665936 | 0.020633033 | |
| hsa-miR-206 | 31.35934975 | 0.3786274 | 2.424188071 | 0.021099703 | |
| hsa-miR-3187-5p | 24.84167505 | -0.8962384 | -2.366808186 | 0.023474191 | |
| hsa-miR-146a | 25.09430145 | 1.4475159 | 2.399573529 | 0.023936978 | |
| hsa-miR-517# | 31.1082896 | 0.4856575 | 2.360789774 | 0.024120909 | |
| hsa-miR-130b | 29.3360632 | -0.69554485 | -2.357316617 | 0.024287788 | |

7 Vol. 2018, Issue 01

| hsa-miR-200a | 24.30833635 | -0.95845155 | -2.338242734 | 0.02492053 |
|------------------|--------------------------------|-------------|--------------|-------------|
| hsa-miR-299-5p | 25.3406319 | 0.40735705 | 2.314080763 | 0.026169736 |
| hsa-miR-483-3p | 27.4458182 | -0.80552955 | -2.310682326 | 0.026862126 |
| hsa-miR-200b | 24.43627245 | -1.0711679 | -2.296911695 | 0.027584516 |
| hsa-miR-34a | 23.32164945 | 1.11229155 | 2.306203211 | 0.028765759 |
| hsa-miR-363 | 28.08783975 | 0.9611428 | 2.283438761 | 0.02887056 |
| hsa-miR-21# | 27.65452255 | -0.85893615 | -2.227477144 | 0.031921518 |
| hsa-miR-625 | 28.70441055 | 0.98901795 | 2.201772292 | 0.033876062 |
| hsa-miR-934 | 28.9376091 | -1.1932694 | -2.181842067 | 0.035431306 |
| hsa-miR-144 | 26.57500715 | 1.28001735 | 2.175975202 | 0.036636816 |
| hsa-miR-28-5p | 26.6206536 | 0.9144506 | 2.149840334 | 0.038976013 |
| hsa-miR-374b | 25.6924562 | 1.07738825 | 2.129072287 | 0.039896843 |
| hsa-miR-1287 | 30.7139527 | 0.5464396 | 2.120721248 | 0.040598869 |
| hsa-miR-559 | 25.37516275 | -0.9639269 | -2.093759505 | 0.043051703 |
| hsa-miR-16 | 20.7079641 | 0.61409515 | 2.090024936 | 0.043385631 |
| hsa-miR-422a | 31.73138245 | -0.43618595 | -2.030613352 | 0.051080563 |
| hsa-miR-22 | 23.21079415 | 0.7015379 | 2.013561587 | 0.051512891 |
| hsa-miR-31 | 24.2055013 | 1.36200945 | 2.012972117 | 0.051808029 |
| hsa-miR-9 | 29.86422025 | 0.98867865 | 2.008900607 | 0.052376647 |
| hsa-miR-2682 | 31.71242595 | -0.29300055 | -1.996650461 | 0.053350767 |
| hsa-let-7a# | 26.47691995 | 0.5758533 | 1.976738187 | 0.055395972 |
| hsa-miR-29c# | 25.9761347 | 0.8367708 | 1.977295206 | 0.055994364 |
| hsa-miR-483-5p | 29.8680788 | -0.7170832 | -1.942458281 | 0.059520735 |
| hsa-miR-423-3p | 24.3024306 | 0.5268758 | 1.880717317 | 0.067695148 |
| hsa-miR-4516 | 15.1663808 | 0.7559816 | 1.87169274 | 0.069106072 |
| hsa-miR-331-5p | 29.75397915 | 0.54540195 | 1.861309505 | 0.070467054 |
| hsa-miR-486-5p | 25.29719555 | 0.49366285 | 1.850955216 | 0.072390574 |
| hsa-miR-339-3p | 27.45386695 | 0.42801395 | 1.813789201 | 0.077909463 |
| hsa-miR-378b | 27.3473778 | -0.4910585 | -1.807974627 | 0.078633532 |
| hsa-miR-33b | 27.5739101 | 0.5511337 | 1.809235704 | 0.079145316 |
| hsa-miR-30c | 22.3352712 | 0.88364805 | 1.787936387 | 0.081810396 |
| hsa-miR-18a | 29.6545935 | -0.7482391 | -1.78560926 | 0.082864009 |
| hsa-miR-566 | 26.2098305 | -0.55491275 | -1.786615375 | 0.083512205 |
| hsa-miR-3944 | 26.6809559 | -0.5481203 | -1.781717884 | 0.083812955 |
| hsa-miR-423-5p | 24.26223985 | 0.3969786 | 1.76031078 | 0.086460263 |
| hsa-miR-33a | 24.5977212 | 0.56275095 | 1.752026931 | 0.087844695 |
| hsa-miR-219-2-3p | 31.25709005 | 0.30535645 | 1.740985155 | 0.089870468 |
| hsa-miR-125a-5p | 23.55308655 | 0.79933375 | 1.718049039 | 0.093928347 |
| hsa-miR-1285 | 29.1246945 | -0.50452625 | -1.714001351 | 0.095052799 |
| hsa-miR-15b# | a-miR-15b # 29.45490595 | | -1.711580877 | 0.095296274 |
| hsa-miR-193a-5p | 27.88657425 | 0.46327125 | 1.704456152 | 0.097065419 |
| hsa-miR-1273d | 25.55828555 | -0.6731021 | -1.699354427 | 0.097518893 |
| hsa-miR-4454 | 15.2017796 | -0.98903195 | -1.690625947 | 0.099260855 |
| hsa-miR-373# | 25.7436403 | -0.18420255 | -1.666448123 | 0.104029387 |

8 Vol. 2018, Issue 01

| hsa-miR-1268 | 21.1941402 | 0.85487755 | 1.649408005 | 0.107755216 |
|------------------|-------------|-------------|--------------|-------------|
| hsa-miR-93 | 25.3874974 | -0.66449435 | -1.639808116 | 0.110163099 |
| hsa-miR-605 | 29.2925058 | -0.6245109 | -1.614872778 | 0.114984963 |
| hsa-miR-425# | 26.63673985 | -0.4792545 | -1.604445581 | 0.116946305 |
| hsa-miR-4286 | 16.49819445 | -0.90876835 | -1.599542667 | 0.118081575 |
| hsa-let-7a | 21.1478772 | 0.92555255 | 1.589114877 | 0.120344398 |
| hsa-miR-224 | 26.93167345 | 0.91555935 | 1.603333073 | 0.121186155 |
| hsa-let-7f-1# | 28.4389334 | 0.380989 | 1.587978482 | 0.121732096 |
| hsa-miR-650 | 27.8012068 | -0.8874117 | -1.566605666 | 0.126039181 |
| hsa-miR-590-5p | 27.11414205 | 0.3327394 | 1.567640662 | 0.126578009 |
| hsa-miR-296-3p | 25.74392935 | -0.44644515 | -1.542520097 | 0.131552252 |
| hsa-miR-374a | 25.30958305 | 0.86202575 | 1.518348862 | 0.137264061 |
| hsa-miR-19b | 22.3236621 | 0.40619995 | 1.51236616 | 0.138812082 |
| hsa-miR-361-5p | 26.31010785 | 0.60508395 | 1.507141503 | 0.140046769 |
| hsa-miR-146b-3p | 30.7919129 | 0.38168175 | 1.472416161 | 0.149151616 |
| hsa-miR-1306-5p | 29.3238386 | 0.38521345 | 1.470100793 | 0.149786464 |
| hsa-miR-30b | 22.4946482 | 0.83752655 | 1.461738506 | 0.152044836 |
| hsa-miR-4251 | 26.24347615 | -0.4066147 | -1.454992365 | 0.154775248 |
| hsa-miR-554 | 26.9298151 | -0.40861715 | -1.45199967 | 0.155812974 |
| hsa-miR-29b | 22.4214774 | 0.7732205 | 1.444473218 | 0.157019582 |
| hsa-miR-4685-5p | 26.56914765 | 0.7128942 | 1.413234747 | 0.165903946 |
| hsa-miR-324-3p | 23.49381115 | 0.2036009 | 1.414088233 | 0.166525221 |
| hsa-miR-769-5p | 28.93151495 | 0.4491276 | 1.398633999 | 0.170099467 |
| hsa-miR-99b | 24.79095835 | 0.4699214 | 1.38802164 | 0.173403385 |
| hsa-miR-3182 | 22.0917711 | 0.87863845 | 1.369014165 | 0.180092033 |
| hsa-miR-21 | 19.89994595 | -0.47206045 | -1.357314949 | 0.182944616 |
| hsa-miR-3162 | 27.52056975 | 0.27188335 | 1.356724807 | 0.183236798 |
| hsa-miR-3622b-5p | 29.84767925 | -0.341081 | -1.346601703 | 0.187425209 |
| hsa-miR-500a# | 28.988497 | -0.3800054 | -1.332282675 | 0.191417956 |
| hsa-let-7g | 22.5160448 | 0.6208779 | 1.288815201 | 0.20528729 |
| hsa-miR-16-2# | 28.9569723 | 0.3507927 | 1.275855156 | 0.210050585 |
| hsa-miR-639 | 22.70162175 | 0.5668435 | 1.258599219 | 0.216595312 |
| hsa-miR-3184-3p | 27.1632112 | -0.42711215 | -1.251088663 | 0.218889234 |
| hsa-miR-92b | 22.3066823 | 0.3910935 | 1.246320525 | 0.221177981 |
| hsa-miR-324-5p | 24.3754331 | 0.4253259 | 1.226410457 | 0.228249243 |
| hsa-miR-190 | 28.3002212 | 0.68841005 | 1.222898687 | 0.229465423 |
| hsa-miR-1296 | 27.4683343 | 0.31583935 | 1.213811544 | 0.232310267 |
| hsa-miR-5096 | 24.2779367 | 0.46403835 | 1.215719567 | 0.232383243 |
| hsa-miR-629 | 30.4329805 | 0.2767291 | 1.212709864 | 0.232758375 |
| hsa-miR-4492 | 19.08022115 | 0.6325124 | 1.207992999 | 0.23451776 |
| hsa-miR-181a | 25.3775098 | 0.5237116 | 1.205679978 | 0.235489098 |
| hsa-miR-92a | 22.29835705 | 0.3137744 | 1.181328726 | 0.245156721 |
| hsa-miR-421 | 29.46268685 | -0.38368865 | -1.180455185 | 0.245379254 |
| hsa-let-7e | 24.28009255 | 0.7446999 | 1.179494837 | 0.245553482 |

9 Vol. 2018, Issue 01

| hsa-miR-3646 | 24.6028077 | 0.46447895 | 1.176789037 | 0.248227461 |
|-----------------|-------------|-------------|--------------|-------------|
| hsa-miR-371b-5p | 30.71878265 | -0.43535225 | -1.169666136 | 0.250437128 |
| hsa-miR-32 | 25.02813385 | -0.36665765 | -1.166781534 | 0.250819927 |
| hsa-miR-149 | 27.83458655 | -0.60014675 | -1.155921134 | 0.255196798 |
| hsa-miR-138 | 28.02253835 | -0.5825292 | -1.146044004 | 0.261386111 |
| hsa-miR-937 | 28.3246925 | 0.33720585 | 1.139310241 | 0.261714167 |
| hsa-miR-671-3p | 27.9938128 | -0.2949438 | -1.126925869 | 0.268504783 |
| hsa-miR-151b | 25.71631315 | 0.3004291 | 1.118739089 | 0.270347491 |
| hsa-miR-92b# | 20.65776195 | -0.5388198 | -1.108847598 | 0.274473184 |
| hsa-miR-3663-3p | 26.73863275 | -0.4288733 | -1.101674933 | 0.277994139 |
| hsa-miR-4284 | 18.3304225 | -0.37322 | -1.098648887 | 0.278840814 |
| hsa-miR-4532 | 16.5986575 | 0.5003781 | 1.085063268 | 0.285893938 |
| hsa-miR-191 | 24.70332185 | -0.6153625 | -1.080614366 | 0.286991717 |
| hsa-miR-1277 | 30.82314515 | 0.31158625 | 1.038872865 | 0.305508588 |
| hsa-miR-20b | 29.82143965 | 0.36721185 | 1.038761116 | 0.305558152 |
| hsa-miR-4635 | 25.95357065 | -0.40219675 | -1.038598271 | 0.306115543 |
| hsa-miR-1260b | 22.4532214 | -0.4510095 | -1.031106897 | 0.309023332 |
| hsa-miR-124 | 29.18081985 | 0.54780785 | 1.027852462 | 0.314013189 |
| hsa-miR-141 | 23.17711065 | -0.7161285 | -1.022710498 | 0.315071895 |
| hsa-miR-1180 | 26.0773021 | 0.3620099 | 0.988714866 | 0.329822994 |
| hsa-miR-885-5p | 29.4275937 | -0.31758155 | -0.982636826 | 0.332068742 |
| hsa-miR-642b | 27.25053295 | 0.4879913 | 0.979463207 | 0.333822884 |
| hsa-miR-148b | 25.54500595 | 0.2281798 | 0.979304764 | 0.333839677 |
| hsa-miR-762 | 17.59962505 | 0.46696045 | 0.97683529 | 0.334868614 |
| hsa-miR-4698 | 26.5296455 | 0.2940295 | 0.974212547 | 0.337135312 |
| hsa-miR-4263 | 23.76872745 | -0.2930882 | -0.97414815 | 0.337635105 |
| hsa-miR-378d | 24.6378642 | 0.27294275 | 0.962214586 | 0.342030016 |
| hsa-miR-339-5p | 27.75511755 | 0.33064545 | 0.959533798 | 0.343383228 |
| hsa-miR-22# | 27.92357525 | 0.30962125 | 0.941339142 | 0.352745552 |
| hsa-miR-197 | 25.4805562 | 0.22025195 | 0.939742699 | 0.354983429 |
| hsa-miR-379# | 26.18597855 | 0.1408204 | 0.936471092 | 0.355649127 |
| hsa-miR-584-3p | 26.8685574 | -0.61018395 | -0.930093043 | 0.358438609 |
| hsa-miR-1183 | 26.98519235 | 0.2903467 | 0.921756672 | 0.362497576 |
| hsa-miR-335 | 28.5332077 | 0.37705105 | 0.920353413 | 0.363800157 |
| hsa-miR-320a | 21.04389085 | 0.29208245 | 0.903684028 | 0.372040786 |
| hsa-miR-448 | 28.23364305 | 0.30251855 | 0.902264886 | 0.372642657 |
| hsa-miR-375 | 26.4133213 | -0.3852335 | -0.89618551 | 0.375873877 |
| hsa-miR-7 | 28.77767115 | -0.45543415 | -0.895889826 | 0.377980919 |
| hsa-miR-323b-5p | 27.40918575 | -0.3787318 | -0.887247451 | 0.380620946 |
| hsa-miR-1274b | 13.75481125 | -0.3756949 | -0.885158549 | 0.381927799 |
| hsa-miR-181c# | 30.50849865 | 0.2356556 | 0.874434976 | 0.38740319 |
| hsa-miR-744 | 27.20480145 | 0.3506853 | 0.869253007 | 0.390475117 |
| hsa-miR-1234 | 24.93561275 | -0.293629 | -0.860221249 | 0.395251938 |
| hsa-miR-5095 | 26.5877565 | -0.28790035 | -0.85357325 | 0.399280773 |

10 Vol. 2018, Issue 01

| hsa-let-7d | 25 0008752 | 0 48898075 | 0 843168971 | 0 404632823 | |
|-----------------|-------------|------------------------|------------------------|-------------|--|
| hsa-miR-1307 | 25.38789105 | 0.3200131 | 0.824910203 | 0.414760055 | |
| hsa-miR-494 | 25.32735315 | -0.34495905 | -0.82434122 | 0.414970658 | |
| hsa-miR-98 | 27.57443425 | -0.3996101 | -0.823926665 | 0.415170358 | |
| hsa-miR-3180-5p | 17.0559855 | 0.21824015 | 0.806429554 | 0.425238312 | |
| hsa-miR-185 | 26.1815539 | 0.189505 | 0.754060576 | 0.455806273 | |
| hsa-miR-612 | 29.63939555 | -0.26334875 | -0.746922502 | 0.4599483 | |
| hsa-miR-766 | 26.87308365 | -0.21527685 | -0.72760122 | 0.471317294 | |
| hsa-miR-3651 | 25.76222025 | -0.2232142 | -0.727400218 | 0.47152996 | |
| hsa-miR-3191 | 24.8191096 | -0.22560725 | -0.727094849 | 0.471673478 | |
| hsa-miR-4695-3p | 26.3316455 | -0.23 | -0.72431449 | 0.474482712 | |
| hsa-miR-106b | 26.61006545 | -0.3564899 | -0.721599514 | 0.475066425 | |
| hsa-miR-320d | 28.5826086 | 0.19390255 | 0.721857936 | 0.475397793 | |
| hsa-let-7g# | 28.09309415 | 0.19231945 | 0.72164345 | 0.475469554 | |
| hsa-miR-216a | 30.94009165 | -0.2079436 | -0.705383566 | 0.485429561 | |
| hsa-miR-93# | 27.5081386 | -0.1523531 | -0.698294251 | 0.489639785 | |
| hsa-miR-5585-3p | 25.4169486 | 0.1774127 | 0.697320391 | 0.489854914 | |
| hsa-miR-551b# | 28.78316675 | -0.1843535 | -0.693770869 | 0.492655007 | |
| hsa-miR-1972 | 26.7827905 | -0.22763265 | -0.689941928 | 0.494424772 | |
| hsa-miR-326 | 24.25290355 | -0.1539566 | -0.68939688 | 0.495514013 | |
| hsa-miR-1224-3p | 28.53325345 | 0.2251597 | 0.676649703 | 0.50310755 | |
| hsa-miR-3679-5p | 26.4020032 | 0.2771728 | 0.674941659 | 0.504354724 | |
| hsa-miR-151-5p | 25.1502141 | 0.22582085 | 0.659305932 | 0.513933309 | |
| hsa-miR-3619-3p | 28.58486465 | -0.2143546 | -0.655142748 | 0.516554414 | |
| hsa-miR-625# | 25.9377285 | 0.1554537 | 0.625559393 | 0.535343552 | |
| hsa-miR-654-5p | 31.52516395 | 0.11648045 0.623917691 | | 0.536423734 | |
| hsa-miR-302a | 30.84744205 | 0.15741805 | 0.15741805 0.580578711 | | |
| hsa-miR-1268b | 26.0974757 | -0.19846125 | -0.579862391 | 0.567010382 | |
| hsa-miR-25 | 25.29295555 | -0.1389799 | -0.562271552 | 0.577249138 | |
| hsa-miR-323-5p | 25.196418 | 0.15207035 | 0.551788961 | 0.584428268 | |
| hsa-miR-4290 | 30.2469358 | -0.1581287 | -0.544861615 | 0.589035576 | |
| hsa-miR-17 | 24.96355105 | -0.24533295 | -0.529715731 | 0.599870904 | |
| hsa-miR-20b# | 27.6140579 | 0.17891275 | 0.524923087 | 0.603200452 | |
| hsa-miR-202 | 27.629297 | 0.12079885 | 0.523675137 | 0.604147683 | |
| hsa-miR-1299 | 31.63629935 | 0.0845147 | 0.522010887 | 0.6050627 | |
| hsa-miR-19a | 23.68422655 | 0.1386444 | 0.50851605 | 0.614071319 | |
| hsa-miR-205 | 23.1873946 | -0.2737087 | -0.507709419 | 0.614891442 | |
| hsa-miR-642a-3p | 27.61033735 | 0.2242457 | 0.504667643 | 0.61685273 | |
| hsa-miR-3141 | 24.13523625 | 0.09131945 | 0.504959479 | 0.617345024 | |
| hsa-miR-1207-5p | 23.82764015 | 0.35541785 | 0.485376317 | 0.63019722 | |
| hsa-miR-550a# | 29.96839845 | -0.15557395 | -0.48075854 | 0.633444623 | |
| hsa-miR-4664-3p | 27.9946398 | -0.1505473 | -0.478845988 | 0.635584039 | |
| hsa-miR-17# | 25.7515808 | 0.0976056 | 0.474246322 | 0.63818301 | |
| hsa-miR-2277-3p | 24.84175595 | -0.15218825 | -0.462732031 | 0.646370519 | |

11 Vol. 2018, Issue 01

| hsa-let-7f | 23.6711256 | 0.2959151 | 0.461866988 | 0.646877126 |
|-----------------|-------------|-------------|--------------|-------------|
| hsa-miR-564 | 27.23760085 | 0.23435625 | 0.457184877 | 0.65020731 |
| hsa-miR-106a | 25.39988795 | -0.2100676 | -0.444123366 | 0.65981449 |
| hsa-miR-15a | 23.1720913 | 0.17049295 | 0.442231218 | 0.660863024 |
| hsa-miR-300 | 28.623326 | -0.1314028 | -0.414758253 | 0.680740147 |
| hsa-miR-382 | 28.3467667 | -0.1000463 | -0.412582616 | 0.682451735 |
| hsa-miR-1915 | 16.9399378 | 0.1236714 | 0.406935 | 0.686576961 |
| hsa-miR-3689d | 27.98357805 | -0.07652995 | -0.396705564 | 0.694457682 |
| hsa-RNU48-1 | 21.95787005 | 0.3272244 | 0.393264742 | 0.696650292 |
| hsa-miR-574-5p | 25.41036955 | 0.13404955 | 0.380278301 | 0.70585643 |
| hsa-miR-4725-5p | 26.949534 | -0.11933515 | -0.378061612 | 0.707500641 |
| hsa-miR-103-2# | 28.4360144 | 0.1036946 | 0.372475071 | 0.711608704 |
| hsa-miR-1246 | 17.30316425 | -0.17320005 | -0.372342033 | 0.711741213 |
| hsa-miR-3181 | 20.5008378 | -0.1995124 | -0.363505146 | 0.718250828 |
| hsa-miR-20a | 25.0810381 | -0.1477488 | -0.35863641 | 0.722024089 |
| hsa-miR-4306 | 27.22936405 | -0.08594795 | -0.338895232 | 0.736966577 |
| hsa-miR-378g | 27.46283575 | 0.09311515 | 0.337927878 | 0.737281911 |
| hsa-miR-433 | 26.9782495 | -0.2073267 | -0.336341808 | 0.738607559 |
| hsa-miR-301a | 29.73122385 | -0.1412877 | -0.321838932 | 0.749338801 |
| hsa-miR-652 | 27.8164068 | 0.09792065 | 0.320862128 | 0.750088077 |
| hsa-miR-15b | 23.37290045 | 0.1003191 | 0.320445035 | 0.750394543 |
| hsa-miR-129-5p | 28.8794664 | 0.10297905 | 0.315500916 | 0.754186863 |
| hsa-miR-378 | 26.36678715 | 0.0988369 | 0.314487233 | 0.755068288 |
| hsa-miR-665 | 20.0920677 | 0.10787025 | 0.283461241 | 0.778378911 |
| hsa-miR-10a | 25.6904664 | -0.14084815 | -0.283563401 | 0.778868098 |
| hsa-miR-4484 | 28.00819605 | 0.09548285 | 0.269841541 | 0.788761755 |
| hsa-miR-15a# | 28.2211569 | -0.0777877 | -0.257849524 | 0.797924792 |
| hsa-miR-1233 | 25.59041025 | 0.1306009 | 0.246570649 | 0.807044501 |
| hsa-miR-484 | 24.9432688 | -0.0504117 | -0.245186001 | 0.807725846 |
| hsa-miR-1202 | 26.86419775 | 0.0332515 | 0.228171891 | 0.82095575 |
| hsa-miR-103 | 24.32553745 | 0.13688355 | 0.22647014 | 0.822051185 |
| hsa-miR-941 | 27.8593266 | 0.05860165 | 0.224363525 | 0.823677058 |
| hsa-miR-330-3p | 28.72115875 | -0.0720646 | -0.196959293 | 0.844916079 |
| hsa-miR-1254 | 28.54717835 | 0.058288 | 0.1896801 | 0.850581949 |
| hsa-miR-3132 | 27.4959067 | -0.0570482 | -0.185182972 | 0.8545818 |
| hsa-miR-501-5p | 25.8247457 | -0.0753557 | -0.173588229 | 0.863151249 |
| hsa-miR-454 | 28.7386076 | 0.07162315 | 0.17352609 | 0.86317055 |
| hsa-miR-16-1# | 29.34863545 | -0.05301645 | -0.166348808 | 0.86882912 |
| hsa-miR-365b-5p | 30.38777815 | 0.04380215 | 0.158426752 | 0.874978772 |
| hsa-miR-331-3p | 25.5062669 | 0.0446007 | 0.148997565 | 0.882573582 |
| hsa-miR-2355-3p | 30.95855525 | 0.06435495 | 0.140128443 | 0.889626869 |
| hsa-miR-151-3p | 25.15628685 | 0.04211665 | 0.13352093 | 0.894486117 |
| hsa-let-7d# | 24.00656225 | -0.0395099 | -0.133460794 | 0.894544296 |
| hsa-miR-346 | 28.6858022 | -0.04241905 | -0.126901935 | 0.899723074 |

12 Vol. 2018, Issue 01

| hsa-miR-3185 | 25.2378073 | -0.07098325 | -0.122512599 | 0.903142174 |
|-----------------|-------------|-------------|--------------|-------------|
| hsa-miR-4323 | 24.9424088 | -0.04437345 | -0.115628473 | 0.908570377 |
| hsa-miR-3198 | 27.40352145 | 0.0345949 | 0.107008127 | 0.915472693 |
| hsa-miR-3613-5p | 25.59744405 | -0.0395708 | -0.106765334 | 0.915639947 |
| hsa-miR-4499 | 24.6237142 | -0.03937785 | -0.105615673 | 0.916465316 |
| hsa-miR-192 | 27.774702 | 0.04120985 | 0.104152241 | 0.917683785 |
| hsa-miR-1274a | 24.02371645 | 0.0386535 | 0.082935026 | 0.934344551 |
| hsa-miR-1909# | 25.54695015 | -0.02103895 | -0.078541132 | 0.937870115 |
| hsa-miR-194 | 27.88834705 | -0.0250198 | -0.065966097 | 0.947785094 |
| hsa-miR-545 | 29.5629911 | -0.0156341 | -0.050727576 | 0.95983062 |
| hsa-miR-345 | 27.08308965 | -0.01217395 | -0.04508245 | 0.964278115 |
| hsa-miR-1301 | 29.32401765 | 0.0079466 | 0.031756097 | 0.974832864 |
| hsa-miR-3663-5p | 28.97261735 | -0.0061759 | -0.022203476 | 0.982407235 |
| hsa-miR-874 | 26.11694465 | 0.00386435 | 0.017253037 | 0.986327137 |
| hsa-miR-663 | 22.2101501 | 0.0027166 | 0.007669137 | 0.993921278 |
| hsa-7SL-scRNA | 15.94935815 | -0.00258635 | -0.003819258 | 0.996977373 |

Supplemental Table 1: The expression levels of 365 dysregulated miRNAs and two endogenous controls in the BC tissues compared with those in adjacent normal tissues.

Mean Normal ct = qPCR ct value of miRNA in bladder adjacent tissues; FC = fold change; FC > 0 means decreased expression level in cancer tissues compared with adjacent tissues, FC < 0 means increased expression level in cancer tissues.

| miR name | Mean Cancer ct | Mean Normal ct | Log ₂ FC | Fold Change | T-value | P-value |
|-----------------|-------------------|-------------------|---------------------|----------------|----------------|----------|
| hsa-miR-1 | 31.11 | 26.06 | 5.05 | 33.14 | 10.0188 | 6.09E-12 |
| hsa-miR-30a | 25.79 | 22.57 | 3.21 | 9.28 | 9.7216 | 2.11E-11 |
| hsa-miR-133a | 27.60 | 24.39 | 3.21 | 9.26 | 8.9519 | 2.00E-10 |
| hsa-miR-143# | 28.65 | 25.03 | 3.62 | 12.28 | 8.4715 | 4.67E-10 |
| hsa-miR-4328 | 25.12 | 21.03 | 4.09 | 16.99 | 8.7692 | 6.55E-10 |
| hsa-miR-143 | 24.10 | 19.72 | 4.37 | 20.75 | 8.1777 | 1.27E-09 |
| hsa-miR-145 | 22.99 | 18.26 | 4.73 | 26.46 | 8.3910 | 2.74E-09 |
| hsa-miR-376c | 28.97 | 25.37 | 3.60 | 12.13 | 7.9053 | 3.84E-09 |
| hsa-miR-125b | 25.11 | 20.28 | 4.82 | 28.32 | 8.0892 | 5.55E-09 |
| hsa-miR-199b-3p | 25.03 | 20.71 | 4.32 | 19.97 | 8.4551 | 5.84E-09 |
| hsa-miR-100 | 27.55 | 22.96 | 4.59 | 24.08 | 7.9632 | 1.27E-08 |
| hsa-miR-99a | 28.15 | 23.36 | 4.79 | 27.71 | 8.1981 | 1.28E-08 |
| hsa-miR-497 | 27.11 | 24.03 | 3.08 | 8.48 | 7.5693 | 1.69E-08 |
| hsa-miR-376a | 30.03 | 26.43 | 3.61 | 12.17 | 7.7034 | 1.90E-08 |
| hsa-miR-199a-5p | 26.23 | 22.07 | 4.16 | 17.87 | 7.3058 | 2.21E-08 |
| hsa-miR-195 | 26.30 | 23.15 | 3.15 | 8.86 | 6.8696 | 5.41E-08 |
| hsa-miR-154 | 29.72 | 26.57 | 3.15 | 8.86 | 7.2751 | 9.96E-08 |
| hsa-miR-139-5p | 28.73 | 26.55 | 2.18 | 4.54 | 6.6091 | 1.13E-07 |

13 Vol. 2018, Issue 01

| hsa-miR-127-3p | 27.45 | 25.11 | 2.35 | 5.09 | 6.3966 | 2.33E-07 |
|-----------------|-------|-------|-------|-------|---------|----------|
| hsa-miR-150 | 27.99 | 24.13 | 3.86 | 14.55 | 6.3678 | 2.52E-07 |
| hsa-miR-152 | 28.05 | 25.07 | 2.97 | 7.84 | 6.7012 | 2.57E-07 |
| hsa-miR-379 | 31.49 | 29.14 | 2.35 | 5.11 | 6.3446 | 2.63E-07 |
| hsa-miR-140-3p | 28.02 | 25.45 | 2.57 | 5.94 | 6.0036 | 6.91E-07 |
| hsa-miR-136# | 30.24 | 26.85 | 3.39 | 10.45 | 6.0200 | 8.19E-07 |
| hsa-miR-377 | 29.34 | 25.85 | 3.49 | 11.22 | 6.7306 | 8.48E-07 |
| hsa-miR-495 | 30.61 | 27.90 | 2.71 | 6.54 | 6.3051 | 9.28E-07 |
| hsa-miR-136 | 28.45 | 25.06 | 3.39 | 10.49 | 6.1732 | 9.73E-07 |
| hsa-miR-101 | 23.47 | 21.50 | 1.97 | 3.91 | 5.6021 | 2.47E-06 |
| hsa-miR-133b | 29.08 | 27.03 | 2.06 | 4.16 | 5.7448 | 2.57E-06 |
| hsa-miR-337-3p | 28.82 | 26.64 | 2.18 | 4.54 | 5.7657 | 2.90E-06 |
| hsa-miR-29a | 23.15 | 20.63 | 2.52 | 5.72 | 5.8648 | 2.91E-06 |
| hsa-miR-574-3p | 25.23 | 23.35 | 1.88 | 3.67 | 5.5423 | 3.96E-06 |
| hsa-miR-130a | 25.99 | 23.45 | 2.54 | 5.81 | 5.7732 | 4.45E-06 |
| hsa-miR-342-3p | 25.23 | 23.15 | 2.08 | 4.24 | 5.6557 | 5.05E-06 |
| hsa-miR-126# | 24.90 | 22.86 | 2.05 | 4.13 | 5.1135 | 1.24E-05 |
| hsa-miR-222 | 25.34 | 23.36 | 1.97 | 3.92 | 5.0994 | 1.58E-05 |
| hsa-miR-28-3p | 26.90 | 25.61 | 1.29 | 2.44 | 4.7988 | 2.87E-05 |
| hsa-miR-365b-3p | 25.38 | 24.10 | 1.29 | 2.44 | 4.8883 | 3.49E-05 |
| hsa-miR-27b | 24.19 | 22.41 | 1.79 | 3.45 | 4.7126 | 3.89E-05 |
| hsa-let-7c | 26.41 | 24.06 | 2.35 | 5.10 | 4.6752 | 4.04E-05 |
| hsa-miR-342-5p | 30.97 | 29.44 | 1.53 | 2.88 | 4.6693 | 5.39E-05 |
| hsa-miR-431 | 25.68 | 27.39 | -1.71 | -3.27 | -4.4787 | 8.06E-05 |
| hsa-miR-320c | 24.70 | 23.21 | 1.49 | 2.81 | 4.5258 | 8.33E-05 |
| hsa-miR-182 | 26.70 | 28.78 | -2.08 | -4.22 | -4.4854 | 9.35E-05 |
| hsa-miR-551b | 28.47 | 25.33 | 3.14 | 8.81 | 4.4619 | 9.38E-05 |
| hsa-miR-543 | 31.08 | 29.69 | 1.39 | 2.61 | 4.4079 | 9.56E-05 |
| hsa-miR-193b | 24.15 | 23.08 | 1.07 | 2.10 | 4.2799 | 1.39E-04 |
| hsa-miR-451 | 24.01 | 21.90 | 2.11 | 4.32 | 4.2547 | 1.45E-04 |
| hsa-miR-1247 | 23.67 | 22.36 | 1.31 | 2.48 | 4.2604 | 1.50E-04 |
| hsa-miR-140-5p | 30.30 | 28.29 | 2.01 | 4.01 | 4.2463 | 1.56E-04 |
| hsa-miR-142-5p | 27.09 | 24.54 | 2.55 | 5.87 | 4.2429 | 1.56E-04 |
| hsa-miR-126 | 23.02 | 21.17 | 1.85 | 3.61 | 4.1344 | 2.10E-04 |
| hsa-miR-10b | 26.22 | 24.68 | 1.54 | 2.90 | 4.1934 | 2.28E-04 |
| hsa-miR-369-3p | 30.14 | 28.35 | 1.80 | 3.47 | 4.1931 | 2.57E-04 |
| hsa-miR-328 | 26.89 | 25.82 | 1.07 | 2.10 | 4.0529 | 2.64E-04 |
| hsa-miR-338-3p | 28.04 | 25.79 | 2.25 | 4.75 | 4.0157 | 2.89E-04 |
| hsa-miR-183 | 26.64 | 28.48 | -1.84 | -3.57 | -3.9608 | 3.49E-04 |
| hsa-miR-532-5p | 28.10 | 27.06 | 1.04 | 2.06 | 3.8482 | 4.68E-04 |

14 Vol. 2018, Issue 01

| hsa-miR-409-3p | 29.55 | 27.97 | 1.58 | 2.99 | 3.8801 | 5.41E-04 |
|----------------|-------|-------|-------|-------|---------|----------|
| hsa-miR-24 | 23.50 | 21.96 | 1.54 | 2.90 | 3.7752 | 5.87E-04 |
| hsa-miR-132 | 28.07 | 26.45 | 1.63 | 3.09 | 3.8190 | 5.97E-04 |
| hsa-miR-30e# | 26.88 | 25.28 | 1.60 | 3.02 | 3.7311 | 6.74E-04 |
| hsa-miR-429 | 23.52 | 25.04 | -1.51 | -2.86 | -3.7180 | 6.81E-04 |
| hsa-let-7i# | 26.96 | 25.52 | 1.44 | 2.70 | 3.7037 | 7.65E-04 |
| hsa-miR-142-3p | 25.15 | 22.34 | 2.81 | 7.01 | 3.6692 | 7.95E-04 |
| hsa-miR-221 | 27.09 | 25.53 | 1.56 | 2.96 | 3.7036 | 7.97E-04 |
| hsa-miR-4457 | 27.52 | 25.90 | 1.62 | 3.07 | 3.6927 | 8.31E-04 |
| hsa-miR-186 | 25.53 | 24.57 | 0.96 | 1.95 | 3.6399 | 8.80E-04 |
| hsa-miR-425 | 26.33 | 27.34 | -1.01 | -2.02 | -3.6236 | 9.07E-04 |
| hsa-miR-155 | 29.47 | 27.46 | 2.01 | 4.03 | 3.6076 | 9.51E-04 |

Table 2: 70 aberrant miRNAs with P-value < 0.001.

Mean Normal ct = qPCR ct value of mirna in bladder adjacent tissues; Mean Cancerct = qPCR ct value of mirna in bladder cancer tissues; FC = fold change; $Log_2FC > 0$ means decreased expression level in cancer tissues compared with adjacent tissues, $Log_2FC < 0$ means increased expression level in cancer tissues compared with adjacent tissues.

3.4. Developing miRNAs Expression Signatures In Diagnosis of BC

An unpaired T-test (p < 0.05) with a Benjamini Hochberg FDR multiple testing corrections was used to identify significantly dysregulated miRNAs that distinguish BC from normal controls. Accurate classification of BC patients from normal controls is crucial for successful BC treatment; we investigated the diagnostic value of the miRNA-expression profile in BC patients. Among the 70 significant miRNAs (P-value < 0.001) checked (these miRNAs listed in (**Table 2**) with t-value and p-value), several expression signatures of three or four-miRNAs were developed as predictors of BC from normal controls. These signatures were selected based on a machine learning approach of support vector machine (SVM).

The best 10 groups of miRNA signatures were listed in Table 3. Thereby, in the group 1, the expression levels of miR-133a ($log_2FC = 9.258$; P < 0.00000001) were significant down regulated in BC patients. However, expression of miR-431 ($\log_2 FC =$ -3.268; P< 0.0001) was significant higher in BC tissues than in adjacent normal tissues. In spite of level of miR-4251 (P > 0.1) was slightly higher in BC tissues than in adjacent normal tissues. The results showed that the use of improved comparative Ct method seems to be an easily applicable method with potential for general clinical use that avoids the need for large-scale, high-throughput profiling analyses and was therefore used to develop clinically useful signatures based on tissues biomarkers (Supplemental Figure 1).



16 Vol. 2018, Issue 01

Supplemental Figure 1: Supply the results showed that the use of improved comparative Ct method seems to be an easily applicable method with potential for general clinical use that avoids the need for large-scale, high-throughput profiling analyses and was therefore used to develop clinically useful signatures based on tissues biomarkers.

3.5. Prediction of BC and Control Subjects by Risk Score Analysis

To verify the accuracy and specificity of these three or four miRNA signatures to be used as BC biomarkers, we further assessed the 3 miRNAs in the former set consisting of 38 samples, including of 19 BC tissue samples and 19 matched adjacent normal tissue samples (**Figure 3**). The areas under the ROC curve (AUC) were 1 with 100% sensitivity and 100% specificity was respectively (**Figure 4**).



Figure 3: The classification performance of the three selected miRNAs on 19 bladder cancer tissues compared with the 19 matched patients' adjacent tissues. SVM prediction probability for 38 samples with an error of 0.



Figure 4: The classification performance of the three selected miRNAs on 19 bladder cancer tissues compared with the 19 matched patients' adjacent tissues. The receiver operating characteristic curve (area under the curve = 1) estimation for the miRNA panel in the BC and the matched adjacent tissue groups.

3.6. Double Blind Test

To verify the accuracy and specificity of identified miRNA signatures to be used as BC biomarkers, another 21 samples (including 11 BC tissue samples and 10 adjacent normal bladder tissue samples) were tested in a double-blind fashion to validate the predictive ability of the miRNA-based signatures for BC diagnosis. The accuracy 95.2% of the signature consisting of hsa-miR-133a, hsa-miR-431 and hsa-miR-4251 with 100% sensitivity and 90% specificity was respectively (**Figure 5**). Especially, 10 of stage I BC tissues were confirmed by cytology.



Figure 5: Validation of BC miRNA Expression Signature Model 1 in another 21 samples. 11 bladder cancer tissues and 10 matched adjacent controls were separated by SVM score, Cancer > = 0.5, Normal < 0.5.

4. Discussion

In order to find specific signatures of BC tissuebased miRNAs, a comparative study was performed using a qRT-PCR array platform to profile 19 BC tissue samples from patients with BC and 19 adjacent normal tissue samples from matched patients.The study revealed that 70 aberrant miRNAs (**Table 2**)hsa-miR-96, hsa-miR-182, hsa-miR-183, hsa-miR-

429, hsa-miR-425, hsa-miR-431 are overexpressed in bladder cancer comparing to the normal. Among these miRNAs, miR-96, miR-182 and miR-183 are clustered at one locus of the chromosome 7 [15]. miR-429 belongs to the miR-200 family, which is clustered on the chromosomes 12, we further found that other members (200a/b/c) of miR200 family are also overexpressed in bladder cancer comparing to the normal (**Supplement table 1**). Both two miRNA clusters are well-known oncogenic miRNA clusters that have been extensively reported to involve in tumor genesis in ovarian cancer and other types of cancer [16-19] suggesting theses miRNAs may be involved in bladder cancer and ovarian cancer development.

The ten groups of miRNAs signatures have been selected to discriminate the BC from the normal

controls with 100% sensitivity and 100% specificity, suggesting their potential value for diagnosis of BC (Table 3, Figure 5). These selected signatures all contain hsa-miR-133a that means hsa-miR-133a may play a key role in discriminating BC from normal controls. The number one signature includes three miRNAs, hsa-miR-133a, hsa-miR-431 and hsa-miR-4251. Hsa-miR-133a was significantly down regulated and hsa-miR-431 was significantly upregulated in BC. However, the expression of hsamiR-4251 wasn't changed between BC and normal controls. Furthermore, these signatures can predict BC with statistically significant high accuracy over 95% in double blind test. More importantly, these miRNA signatures could effectively distinguish early stage (25 cases in stage I) of BC tissues from normal controls, suggesting their potential valuein detection of BC at early stage.

| miRNA | marker1 | marker2 | marker3 | marker4 | Accuracy | AUC |
|-----------|--------------|----------------|----------------|--------------|----------|-----|
| signature | | | | | | |
| s groups | | | | | | |
| 1 | hsa-miR-133a | hsa-miR-431 | hsa-miR-4251 | - | 1 | 1 |
| 2 | hsa-miR-133a | hsa-miR-296-3p | hsa-miR-4251 | - | 1 | 1 |
| 3 | hsa-miR-133a | hsa-miR-10b | hsa-miR-4251 | - | 1 | 1 |
| 4 | hsa-miR-133a | hsa-miR-449b | hsa-miR-484 | - | 1 | 1 |
| 5 | hsa-let-133a | hsa-miR-7a# | hsa-miR-431 | hsa-miR-4251 | 1 | 1 |
| 6 | hsa-let-133a | hsa-miR-449b | hsa-miR-7a# | hsa-miR-4251 | 1 | 1 |
| 7 | hsa-miR-133a | hsa-miR-449b | hsa-miR-1260 | hsa-miR-4251 | 1 | 1 |
| 8 | hsa-miR-133a | hsa-miR-449b | hsa-miR-296-3p | hsa-miR-4251 | 1 | 1 |
| 9 | hsa-miR-133a | hsa-miR-449b | hsa-miR-484 | hsa-miR-4251 | 1 | 1 |
| 10 | hsa-miR-133a | hsa-miR-181c# | hsa-miR-326 | hsa-miR-4251 | 1 | 1 |

Table 3: 10 best groups of miRNA signatures.

A previous study[**20**] has reported the expression level of miR-133a, miR-133b, miR-1 and miR-99a have down-regulated, however, miR-182 has upregulated in BC by using microarray in large number of samples. These miRNAs might be involved in the tumorigenesis and deterioration of BC. Our results confirmed the previous findings, and further demonstrated that the signatures containing miR-133a can diagnose BC even at early stage with high sensitivity and specificity.

miR-133a is involved in numerous pathways related with different biological processes, cellular components, molecular functions, and some cell signaling, such as caspase signaling, insulin/IGF signaling, and EGFR signaling pathways (supplemental Figure 2). The connecting between importance of miR-133a in tumorigenesis and significantly down regulation of miR-133a expression in BC has shed light in prospective molecular mechanism of miRNA-133a and other miRNAs in the tumorigenesis of BC.



Supplemental Figure 2: miR-133a is involved in numerous pathways related with different biological processes, cellular components, molecular functions, and some cell signaling, such as caspase signaling, insulin/IGF signaling, and EGFR signaling pathways.

As reported from other investigators [21,22], our results also showed that, miR-1, miR-133a, miR-133b, miR-143, miR-145 and miR-10b, are frequently downregulated in BC tissues, suggesting a major role of these tumor suppressor miRNAs in bladder carcinoma. Chief of all frequently downregulated miRNAs, the miR-133a was the only one important miRNA shown up in all ten BC diagnosis signatures (Table 3). miR-133a was one member of the miR-133 family, which was first experimentally characterized in mice[23]. miR-133 and miR-1 are clustered on the same chromosomal locus in the human genome (18q11.2) and share the same transcriptional unit, which have shown their essential functions in controlling skeletal muscle proliferation and differentiation[25]. Genes encoding miR-133 (miR-133a-1,miR-133a-2 and miR-133b) are transcribed as bicistronic transcripts together with miR-1-2 and miR-1-1. We had analyzed potential target gene and function of miR-133a by using www.mirnet.ca(supplemental Figure 3). We recognized that there is a correlation between miR-133a and miR-1 by target on TAGLN2 and LASP1 just like two references are reported [22,25].In agreement with our study, miR-133a has been reported to be frequently down regulation in several types of cancer, including BC[22, 26-28]. miR-133a appears to act as tumor suppressors by inhibiting cell proliferation, invasion, migration, and apoptosis [22,25].



Supplemental Figure 3: Genes encoding miR-133 (miR-133a-1, miR-133a-2 and miR-133b) are transcribed as bicistronic transcripts together with miR-1-2 and miR-1-1. We had analyzed potential target gene and function of miR-133a by using www.mirnet.ca.

5. Acknowledgements

Each author has indicated that he or she has met the journal's requirements for authorship. This work was funded by Project of Shanghai Science and Technology Committee (No. 17401930400). There is no conflict of interest for any of the authors in any aspects of this article.

References

- 1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, et al. (2017) Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 71: 96-108.
- 2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108.
- 3. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7-30.
- 4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, et al. (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-132.
- Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, et al. (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68: 549-553.
- 6. Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Cancer 107: 982-990.

- Schmitz-Drager BJ, Todenhofer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, et al. (2014) Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol 32: 1061-1068.
- 8. Saxena S, Jonsson ZO, Dutta A (2003) Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 278: 44312-44319.
- Wu L, Belasco JG (2008) Examining the influence of microRNAs on translation efficiency and on mRNA deadenylation and decay. Methods Enzymol 449: 373-393.
- Wu L, Fan J, Belasco JG (2006) MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 103: 4034-4039.
- 11. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, et al. (2013) Plasma microRNA profiles for bladder cancer detection. Urol Oncol 31: 1701-1708.
- 12. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, et al. (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28: 655-661.
- 13. Jiang X, Du L, Wang L, Li J, Liu Y, et al. (2015) Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 13: 854-862.
- 14. Wu P, Cao Z, Wu S (2016) New Progress of Epigenetic Biomarkers in Urological Cancer. Dis Markers 2016: 9864047.
- 15. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414.
- 16. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, et al. (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114: 457-464.
- Liu Z, Liu J, Segura MF, Shao C, Lee P, et al. (2012) MiR-182 overexpression in tumourigenesis of highgrade serous ovarian carcinoma. J Pathol 228: 204-215.
- 18. Segura MF, Hanniford D, Menendez S, Reavie L,

Zou X, et al. (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 106: 1814-1819.

- Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, et al. (2014) A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One 9: e96472.
- 20. Wei Y, He R, Wu Y, Gan B, Wu P, et al. (2016) Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues. Tumour Biol 37: 12555-12569.
- Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, et al. (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132: 2479-2491.
- 22. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, et al. (2011)The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104: 808-818.
- Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, et al. (2002) Identification of tissuespecific microRNAs from mouse. Curr Biol 12: 735-739.
- 24. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, et al. (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38: 228-233.
- 25. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, et al. (2012) Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 30: 434-443.
- 26. Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, et al. (2010) The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol Mar 57: 398-406.
- 27. Catto JW, Miah S, Owen HC, Bryant H, Myers K, et al.(2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69: 8472-81.
- Song T, Xia W, Shao N, Zhang X, Wang C, et al. (2010) Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 11: 905-911.

Copyright: ©2018 Jianming Guo *, Ruoying Tan**, Zengxia Li ***. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permit unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

20 Vol. 2018, Issue 01